Description
Reslip Pharmacodynamics
Blocker of H1-histamine receptors from the group of ethanolamines. It has a hypnotic, antihistamine, sedative and m-cholinoblocking effect. It shortens the time of falling asleep, increases the duration and quality of sleep, does not change the phase of sleep. Duration of action – 6-8 hours.
Indications
Transient sleep disorders.
Contraindications .
Hypersensitivity to doxylamine and other ingredients of the drug, or to other antihistamines; closed-angle glaucoma or a family history of closed-angle glaucoma; urethral and prostate diseases, accompanied by urine outflow disorders; lactose intolerance, lactase deficiency, glucose-galactose malabsorption; children and adolescents under 15 years of age.
Caution
Patients with a history of apnea – due to the fact that doxylamine may aggravate nocturnal apnea syndrome (sudden respiratory arrest in sleep). Patients older than 65 years of age – due to possible dizziness and delayed reactions with the risk of falls (e.g., when waking up at night after taking sleeping pills), as well as due to a possible increase in the elimination half-life. Patients with renal and hepatic insufficiency (the elimination half-life may be prolonged).
Administration during pregnancy and breastfeeding
On the basis of well controlled trials, doxylamine can be used in pregnant women during the whole period of pregnancy.
Rezlip® administration during breast feeding is contraindicated. If it is necessary to apply the drug during breast feeding, breast feeding must be discontinued.
Dosage and administration method
- Orally. By ? – 1 tablet a day, with some fluid, 15-30 minutes before going to sleep.
- If the treatment is ineffective, the dose can be increased to two tablets, according to a doctor’s recommendation.
- The duration of treatment is from 2 to 5 days; if the insomnia persists, it is necessary to consult a physician.
- Use in special patient groups
- Patients with renal and hepatic insufficiency:
- Due to evidence of increased plasma concentrations and decreased plasma clearance of doxylamine, downward dose adjustment is recommended.
- Use in patients over 65 years of age:
- H1-histamine receptor blockers should be administered with caution in this group of patients due to possible dizziness and delayed reactions with the risk of falls (e.g., in nighttime awakenings after taking sleeping pills). Due to the data on increased plasma concentrations, decreased plasma clearance and increased half-life, a downward adjustment of the dose is recommended.
